Cardiovascular Risk Assessment: ASCVD, Framingham, and Statin Therapy Explained

Cardiovascular disease (CVD) kills more people every year than any other cause of death worldwide. According to the World Health Organization, approximately 17.9 million people die from cardiovascular disease annually, accounting for 32% of all global deaths. The majority of these deaths — heart attacks and strokes — are preventable. Identifying which individuals are at elevated risk and targeting preventive therapy accordingly is one of the highest-value interventions in all of medicine.

This is where cardiovascular risk calculators come in. Tools like the Pooled Cohort Equations (ASCVD), the Framingham Risk Score, and the Reynolds Risk Score allow clinicians and patients to estimate the probability of a major cardiovascular event over the next 10 years — and to use that probability to guide shared decision-making about lifestyle changes, medications, and further testing.

This guide explains how each calculator works, when to use each one, how to interpret the results, and how to translate risk estimates into clinical action.

This guide is for educational purposes only and does not substitute for professional medical advice. Always discuss your cardiovascular risk with a qualified healthcare provider before making any changes to your treatment plan.

---

Why Cardiovascular Risk Stratification Matters

Not everyone with elevated cholesterol or mildly elevated blood pressure needs a statin or antihypertensive medication. Conversely, some patients with seemingly modest risk factors carry a surprisingly high absolute probability of a heart attack or stroke within the next decade.

Risk stratification solves this problem by combining multiple risk factors into a single numeric estimate. Research consistently shows that statin therapy reduces major cardiovascular events by 25–35% in appropriately selected patients — a benefit that only materializes when the right patients are treated. Treating low-risk patients exposes them to drug costs, potential side effects, and the psychological burden of a medical label without meaningful benefit. Under-treating high-risk patients allows preventable events to occur.

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease explicitly endorses the use of validated risk calculators to drive shared decision-making conversations between clinicians and patients. The 10-year ASCVD risk score is now the centerpiece of primary prevention guidelines in the United States.

What "Primary Prevention" Means

Primary prevention refers to preventing a first cardiovascular event — a heart attack, stroke, or cardiovascular death — in a person who has not yet experienced one. This is distinct from secondary prevention, which involves preventing recurrent events in patients who have already had a myocardial infarction, stroke, or coronary revascularization. Patients in the secondary prevention category are already considered very high risk and are treated aggressively regardless of their calculated score.

---

The Pooled Cohort Equations (ASCVD Risk Score)

The Pooled Cohort Equations (PCE), commonly referred to as the ASCVD risk score, are the primary cardiovascular risk tool endorsed by the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. They are designed to estimate the 10-year risk of a first atherosclerotic cardiovascular disease (ASCVD) event, defined as:

• Non-fatal myocardial infarction (heart attack)
• Fatal coronary heart disease
• Fatal or non-fatal stroke

This composite endpoint is broader than the Framingham Risk Score's original focus on coronary heart disease alone, which makes the ASCVD numbers inherently higher and not directly comparable to Framingham estimates.

Variables Used in the ASCVD Calculation

The Pooled Cohort Equations incorporate the following inputs:

| Variable | Details | |---|---| | Age | 40–79 years | | Sex | Male or Female | | Race | White or African American (separate equations) | | Total cholesterol | mg/dL | | HDL cholesterol | mg/dL | | Systolic blood pressure | mmHg | | Blood pressure treatment | Yes/No | | Diabetes | Yes/No | | Current smoking | Yes/No |

The equations use a Cox proportional hazards model derived from pooling several long-term cohort studies including the Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular Health Study (CHS), and the Framingham Original and Offspring Cohorts.

Importantly, separate equations exist for White and African American patients. African Americans carry a higher absolute 10-year ASCVD risk partly due to higher prevalence of hypertension, and the separate equations attempt to account for this epidemiologic difference.

How to Interpret the 10-Year ASCVD Score

The 2018 ACC/AHA Cholesterol Guideline defines four risk categories based on the 10-year ASCVD estimate:

| Risk Category | 10-Year ASCVD Score | Typical Approach | |---|---|---| | Low risk | <5% | Lifestyle counseling; statin generally not indicated | | Borderline risk | 5% to <7.5% | Discuss risk enhancers; consider statin if enhancers present | | Intermediate risk | 7.5% to <20% | Statin therapy recommended; discuss intensity | | High risk | ≥20% | High-intensity statin recommended |

For borderline risk patients (5–7.5%), the guidelines recommend a clinician-patient risk discussion and, if uncertainty remains, consideration of a coronary artery calcium (CAC) score to further refine risk.

Known Limitations of the ASCVD Score

The Pooled Cohort Equations are a powerful tool but carry several well-documented limitations:

1. Possible overestimation: Multiple validation studies have found the PCE may overestimate 10-year risk by 75–150% in contemporary cohorts, possibly because the derivation datasets are older (reflecting higher background CVD rates) and because CVD prevention has improved significantly since those cohorts were assembled.

2. Race/ethnicity generalizability: The equations were derived primarily from White and African American populations. They have not been validated in Hispanic, Asian, or South Asian populations, and may underestimate risk in South Asians in particular.

3. Age ceiling: The equations are only validated for ages 40–79. Young adults with severe hyperlipidemia or familial hypercholesterolemia require different approaches.

4. Does not capture lifetime risk: The 10-year horizon may underestimate the importance of risk factor burden in younger patients. Lifetime risk estimates (available in some calculators) can supplement 10-year estimates in people aged 40–59.

Use the ASCVD Risk Calculator on this site to calculate your personal 10-year risk.

---

The Framingham Risk Score

The Framingham Risk Score (FRS) originated from the landmark Framingham Heart Study, one of the most important longitudinal cardiovascular studies in medical history. The original Framingham Risk Score was published in 1998 by Wilson et al. and was subsequently updated in 2008 by D'Agostino et al.

Original 1998 vs. Updated 2008 Framingham Score

The 1998 version was designed to predict 10-year risk of hard coronary heart disease (CHD) events — specifically non-fatal MI and coronary death. It uses sex-specific point scoring systems based on age, total or LDL cholesterol, HDL cholesterol, blood pressure, diabetes, and smoking status.

The 2008 updated version (also called the Framingham General Cardiovascular Risk Score) broadened the endpoint to include:

• Coronary heart disease
• Stroke
• Peripheral arterial disease
• Heart failure

This expanded endpoint provides a total CVD risk rather than just coronary risk, making it more comprehensive but also producing higher overall risk estimates.

Framingham Variables

| Variable | 1998 Version | 2008 Version | |---|---|---| | Age | Yes | Yes | | Sex | Yes | Yes | | Total cholesterol | Yes | Yes | | HDL cholesterol | Yes | Yes | | Systolic BP | Yes | Yes | | BP treatment | Yes | Yes | | Diabetes | Yes | Yes | | Smoking | Yes | Yes | | BMI | No | Yes (optional) |

When Framingham Is Preferred Over ASCVD

The Framingham Risk Score remains valuable in several situations:

• International use: Framingham has been validated and recalibrated in numerous international cohorts. In many countries outside the US, Framingham-based tools are the standard of care.
• Hard CHD endpoint: When clinicians specifically want to estimate coronary heart disease risk (rather than the composite ASCVD endpoint), the 1998 Framingham CHD score is appropriate.
• Older patients and research settings: Framingham has a much longer track record and more published validation data than the PCE.
• Non-White/Non-African American patients: When the PCE race-specific equations are inapplicable, a recalibrated Framingham score may be more appropriate.

Use the Framingham Risk Calculator on this site to compare your Framingham estimate alongside your ASCVD score.

---

The Reynolds Risk Score

The Reynolds Risk Score, developed by Paul Ridker and colleagues at Brigham and Women's Hospital, was published in 2007 (women) and 2008 (men). It was specifically designed to improve upon Framingham's risk prediction in patients who appear to be at intermediate risk by conventional scoring.

What Makes Reynolds Different

Reynolds incorporates two variables not included in Framingham or ASCVD:

1. High-sensitivity C-reactive protein (hsCRP): An inflammatory biomarker that independently predicts cardiovascular events. The landmark JUPITER trial demonstrated that patients with LDL <130 mg/dL but hsCRP >2.0 mg/L benefited from rosuvastatin, reducing major cardiovascular events by 44%.

2. Family history of premature MI: A parent who had a heart attack before age 60 (in women's Reynolds) or age 65 (in men's Reynolds) substantially increases risk beyond what traditional risk factors capture.

Reynolds Risk Score Variables

| Variable | Notes | |---|---| | Age | Continuous | | Systolic BP | mmHg | | Total cholesterol | mg/dL | | HDL cholesterol | mg/dL | | hsCRP | mg/L | | Hemoglobin A1c | If diabetic | | Smoking status | Current smoker Yes/No | | Family history of premature MI | First-degree relative <60 years (women) / <65 years (men) |

When to Use Reynolds

The Reynolds Risk Score is most valuable when:

• A patient's Framingham or ASCVD score is in the borderline or intermediate range (5–20%) and the clinician wants to refine the estimate before deciding on statin therapy
• The patient has elevated hsCRP (>2.0 mg/L) suggesting subclinical inflammation
• There is a strong family history of premature coronary disease that conventional calculators fail to capture
• The patient is a woman: Reynolds was particularly developed to address the known underestimation of cardiovascular risk in women by older scoring systems

Studies have shown Reynolds reclassifies approximately 40–50% of intermediate-risk women into either lower or higher risk categories compared to Framingham — with a net improvement in risk discrimination.

---

Risk Enhancers Beyond Calculators

For patients who fall into the borderline or intermediate risk categories, guideline-endorsed risk enhancers can help tip the shared decision-making conversation toward or away from statin therapy. These are conditions and biomarkers that confer elevated cardiovascular risk beyond what traditional calculators capture.

Coronary Artery Calcium (CAC) Score

The coronary artery calcium score, measured by non-contrast cardiac CT, is the most powerful risk-enhancing test available. It directly quantifies atherosclerotic plaque burden in the coronary arteries.

| CAC Score | Interpretation | |---|---| | 0 | Very low 10-year ASCVD risk; can defer statin in many borderline/intermediate patients | | 1–99 | Mild coronary calcification; statin discussion warranted | | 100–299 | Moderate calcification; statin generally recommended | | ≥300 or ≥75th percentile for age/sex | High calcification; high-intensity statin strongly favored |

A CAC score of 0 is particularly powerful. Studies show that a zero CAC confers a 10-year event rate below 5% even in patients with multiple traditional risk factors, potentially allowing statin therapy to be safely deferred while emphasizing lifestyle modification.

High-Sensitivity CRP (hsCRP)

An hsCRP >2.0 mg/L suggests elevated systemic inflammation and predicts cardiovascular events independently of LDL. The 2019 ACC/AHA guidelines list hsCRP >2.0 mg/L as a formal risk enhancer favoring statin initiation in borderline/intermediate risk patients.

Additional ACC/AHA-Endorsed Risk Enhancers

• Ankle-brachial index (ABI) <0.9: Indicates peripheral arterial disease and systemic atherosclerosis
• Chronic kidney disease (CKD): eGFR <60 mL/min/1.73m² independently elevates cardiovascular risk. Calculate your kidney function at eGFR Calculator
• Metabolic syndrome: Central obesity, elevated triglycerides, low HDL, elevated fasting glucose, and elevated blood pressure — a cluster that confers risk beyond individual components
• Premature menopause (<40 years): Associated with accelerated cardiovascular aging in women
• Preeclampsia or pregnancy-related hypertension: An underrecognized risk factor for long-term CVD in women
• Inflammatory diseases: Rheumatoid arthritis (1.5–2x increased ASCVD risk), psoriasis (especially severe/systemic), systemic lupus erythematosus, and inflammatory bowel disease
• HIV infection: Antiretroviral therapy and chronic immune activation both accelerate atherosclerosis; ASCVD risk is 1.5–2x elevated in well-controlled HIV
• South Asian ethnicity: Studies show South Asians have higher ASCVD event rates than predicted by PCE; some experts recommend applying a 1.5x multiplier

---

LDL Targets and Statin Therapy: 2019 ACC/AHA Guidelines

Statin therapy is the cornerstone of pharmacologic ASCVD prevention. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease and the 2019 Cholesterol Guideline both provide detailed frameworks for statin initiation and LDL targets.

When to Start a Statin for Primary Prevention

| Clinical Scenario | Recommendation | |---|---| | LDL ≥190 mg/dL (familial hypercholesterolemia) | High-intensity statin regardless of calculated risk | | Diabetes mellitus, age 40–75 | Moderate-intensity statin; high-intensity if 10-year ASCVD ≥20% | | 10-year ASCVD ≥20% (high risk) | High-intensity statin to reduce LDL ≥50% | | 10-year ASCVD 7.5–19.9% (intermediate) | Moderate- to high-intensity statin recommended | | 10-year ASCVD 5–7.4% (borderline) | Discuss; add statin if risk enhancers present | | 10-year ASCVD <5% (low risk) | Lifestyle counseling; statin generally not indicated |

LDL Goals by Risk Category

| Risk Category | LDL-C Goal | |---|---| | Very high risk (secondary prevention) | <55 mg/dL (some guidelines <50 mg/dL) | | High risk (primary prevention, ≥20%) | <70 mg/dL | | Intermediate risk (7.5–19.9%) | ≥50% LDL reduction from baseline | | Borderline/Low risk | <100 mg/dL general target |

Use the LDL Calculator to estimate your LDL-C, and the Cholesterol Ratio Calculator to assess your total:HDL ratio.

Statin Intensity Tiers

Statins are classified by their expected LDL-lowering potency:

High-Intensity Statins (expected LDL reduction ≥50%):

• Atorvastatin 40–80 mg/day
• Rosuvastatin 20–40 mg/day

Moderate-Intensity Statins (expected LDL reduction 30–49%):

• Atorvastatin 10–20 mg/day
• Rosuvastatin 5–10 mg/day
• Simvastatin 20–40 mg/day
• Pravastatin 40–80 mg/day
• Fluvastatin 80 mg/day

Low-Intensity Statins (expected LDL reduction <30%):

• Simvastatin 10 mg/day
• Pravastatin 10–20 mg/day
• Lovastatin 20 mg/day

Beyond Statins: Ezetimibe and PCSK9 Inhibitors

When maximum-tolerated statin therapy fails to reach LDL targets, additional agents are available:

Ezetimibe: Inhibits intestinal cholesterol absorption. Reduces LDL by an additional 15–20% on top of statin therapy. The IMPROVE-IT trial demonstrated ezetimibe added to statin therapy further reduced cardiovascular events in post-ACS patients. Widely used as the first add-on therapy due to favorable safety profile and generic availability.

PCSK9 inhibitors (evolocumab, alirocumab): Monoclonal antibodies that dramatically increase hepatic LDL receptor expression. Can reduce LDL by 50–60% on top of maximally tolerated statin. FOURIER and ODYSSEY OUTCOMES trials showed significant cardiovascular event reduction. Reserved for very high-risk patients (secondary prevention, FH) due to high cost.

Inclisiran: Small interfering RNA targeting PCSK9 mRNA. Administered as a subcutaneous injection twice yearly, offering comparable LDL reduction to PCSK9 inhibitors with a convenient dosing schedule.

Bempedoic acid: An oral ATP-citrate lyase inhibitor that reduces LDL by ~18% and can be used in statin-intolerant patients, as it is only activated in the liver and does not cause muscle-related side effects.

---

Non-Statin Risk Factor Management

Statin therapy works best when combined with comprehensive cardiovascular risk factor control. Isolated LDL reduction with a statin while ignoring blood pressure, smoking, and lifestyle is an incomplete preventive strategy.

Hypertension Management

Elevated blood pressure is the single most important modifiable cardiovascular risk factor globally. The 2017 ACC/AHA Hypertension Guideline classifies blood pressure as follows:

| Category | Systolic | Diastolic | |---|---|---| | Normal | <120 mmHg | <80 mmHg | | Elevated | 120–129 mmHg | <80 mmHg | | Stage 1 Hypertension | 130–139 mmHg | 80–89 mmHg | | Stage 2 Hypertension | ≥140 mmHg | ≥90 mmHg |

Every 20 mmHg increase in systolic BP doubles the risk of cardiovascular death. Treating hypertension reduces stroke risk by approximately 35–40% and coronary heart disease risk by 20–25%. Use the Blood Pressure Calculator to assess your readings.

Diabetes Management

Diabetes mellitus roughly doubles cardiovascular risk. Patients with diabetes and a 10-year ASCVD risk ≥20% should receive high-intensity statin therapy. Newer diabetes medications — particularly GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) — have demonstrated independent cardiovascular event reduction in trials and are now recommended in high-risk patients regardless of glycemic control.

Smoking Cessation

Smoking is one of the most powerful cardiovascular risk factors, roughly doubling the risk of coronary heart disease. It also substantially reduces HDL-C. Complete cessation, even in long-term smokers, reduces cardiovascular risk within 1–2 years. Pharmacologic support (varenicline, bupropion, nicotine replacement therapy) significantly improves quit rates and should be offered to all smokers.

Diet and Physical Activity

A Mediterranean-style or DASH diet reduces cardiovascular events by approximately 25–30% in high-risk patients (PREDIMED trial). Regular aerobic exercise (150+ minutes per week of moderate-intensity activity per AHA guidelines) lowers LDL by 5–10%, raises HDL by 5%, reduces blood pressure, and improves insulin sensitivity. Weight loss of 5–10% of body weight in overweight individuals substantially reduces cardiovascular risk factors. Assess your BMI using the BMI Calculator.

---

Special Populations

Young Adults with Familial Hypercholesterolemia (FH)

Familial hypercholesterolemia affects approximately 1 in 250–500 individuals and is characterized by markedly elevated LDL-C from birth due to genetic mutations in the LDL receptor pathway. Patients with heterozygous FH typically have LDL-C of 190–400 mg/dL. Untreated, they develop coronary artery disease 20–30 years earlier than the general population.

The ACC/AHA guidelines recommend initiating high-intensity statin therapy in all patients with LDL ≥190 mg/dL regardless of calculated ASCVD risk. Importantly, the 10-year risk calculators will underestimate lifetime risk in FH patients because they use current LDL levels rather than accounting for decades of elevated LDL exposure. Cascade screening of first-degree relatives is strongly recommended.

Women

Women have been historically underrepresented in cardiovascular risk research, and older calculators (including early Framingham versions) underestimated their risk. Several female-specific risk factors deserve recognition:

• Premature cardiovascular disease in women often presents as microvascular angina or spontaneous coronary artery dissection (SCAD) rather than obstructive coronary disease
• Pregnancy complications including preeclampsia, gestational hypertension, gestational diabetes, and preterm birth are now recognized as risk-enhancing factors per 2018 guidelines
• Premature menopause (<40 years) is associated with accelerated vascular aging
• Polycystic ovary syndrome (PCOS) confers increased metabolic and cardiovascular risk
• The Reynolds Risk Score was specifically developed for women and may provide better risk discrimination than ASCVD or Framingham in female patients

South Asian Patients

Multiple studies have demonstrated that South Asians (individuals with heritage from India, Pakistan, Bangladesh, Sri Lanka, Nepal) have a 2–3 times higher rate of coronary heart disease compared to White Europeans, even after adjustment for traditional risk factors. South Asians tend to develop CVD at younger ages, have higher rates of insulin resistance and metabolic syndrome, and carry more visceral adiposity relative to BMI.

Current ACC/AHA guidelines list South Asian ethnicity as a formal risk enhancer. Some experts recommend applying a 1.5x multiplier to ASCVD scores in South Asian patients, though this has not been formally validated. Clinicians should consider more aggressive risk factor management in this population.

HIV-Positive Patients

Well-controlled HIV on antiretroviral therapy (ART) is associated with a 1.5–2x increase in cardiovascular risk. Both the direct effects of HIV-related immune activation and the metabolic effects of certain ART regimens (particularly older protease inhibitors) contribute to accelerated atherosclerosis. HIV is formally listed as a risk enhancer in the 2019 ACC/AHA Cholesterol Guideline, and clinicians caring for HIV patients should calculate ASCVD risk and manage cardiovascular risk factors proactively.

---

Using the Cardiovascular Risk Calculators on This Site

This site offers several calculators to comprehensively assess your cardiovascular risk profile:

• ASCVD Risk Calculator: Calculate your 10-year ACC/AHA Pooled Cohort Equations score
• Framingham Risk Calculator: Compare your 10-year Framingham CHD risk estimate
• LDL Calculator: Estimate your LDL-C using the Friedewald equation
• Cholesterol Ratio Calculator: Assess total cholesterol:HDL and LDL:HDL ratios
• Blood Pressure Calculator: Classify your blood pressure and assess hypertension stage
• BMI Calculator: Calculate body mass index and assess obesity-related cardiovascular risk
• Heart Age Calculator: Compare your actual age to your cardiovascular risk age

For the most accurate risk assessment, use these calculators with results from a fasting lipid panel (total cholesterol, HDL, LDL, triglycerides) and a current blood pressure measurement. Discuss all results with your healthcare provider, who can place them in the context of your full medical history.

---

Frequently Asked Questions

Is the ASCVD score or Framingham Risk Score more accurate?

Neither calculator is universally more accurate — they measure slightly different outcomes and were derived from different populations. The ASCVD Pooled Cohort Equations are the standard for US primary prevention guidelines (ACC/AHA), while Framingham has broader international validation. Multiple studies have found that the PCE may overestimate risk by 75–150% in contemporary populations. For most US patients aged 40–79, the ASCVD score is the recommended starting point per current guidelines.

At what 10-year risk level should I start a statin?

The 2019 ACC/AHA guidelines generally recommend initiating statin therapy for primary prevention at a 10-year ASCVD risk ≥7.5% (intermediate risk), though the decision should be individualized through a clinician-patient discussion. For borderline risk (5–7.5%), statins are considered if risk enhancers are present. For high risk (≥20%), high-intensity statin therapy is strongly recommended.

Can I have a heart attack with low cholesterol?

Yes. Approximately 50% of individuals who suffer myocardial infarctions have LDL-C below 130 mg/dL. Cholesterol is only one component of cardiovascular risk. Other major contributors include hypertension, diabetes, smoking, chronic inflammation (elevated hsCRP), family history, sedentary lifestyle, and obesity. This is why comprehensive risk calculators — not isolated cholesterol values — are the appropriate framework for risk-based decisions.

What is a coronary artery calcium (CAC) score, and should I get one?

A CAC score is derived from a non-contrast cardiac CT scan that quantifies calcified plaque in the coronary arteries. It is the most powerful single test for refining cardiovascular risk in asymptomatic patients. The 2019 ACC/AHA guidelines recommend CAC scoring for borderline (5–7.5%) or intermediate (7.5–20%) risk patients when the decision about starting a statin remains uncertain after a risk discussion. A CAC of 0 indicates a very low near-term event risk and can safely defer statin therapy in many patients.

What is the difference between primary and secondary prevention?

Primary prevention means preventing a first cardiovascular event in someone who has never had a heart attack, stroke, or coronary intervention. Secondary prevention means preventing recurrent events in someone who has already had one. All patients in secondary prevention are treated as very high risk regardless of their calculated score, with the goal of achieving LDL <55 mg/dL.

Does having diabetes automatically mean I need a statin?

Current ACC/AHA guidelines recommend statin therapy for all adults with diabetes aged 40–75. The default recommendation is moderate-intensity statin; high-intensity statin is appropriate if the 10-year ASCVD risk is ≥20% or other high-risk features are present (long duration of diabetes, end-organ damage, proteinuria, CKD). Adults with diabetes under 40 or over 75 require individualized assessment.

How often should I have my cardiovascular risk recalculated?

For adults without known CVD and not currently on statin therapy, the ACC/AHA guidelines suggest recalculating risk every 4–6 years for patients aged 40–79. After a statin is initiated, the focus shifts to monitoring LDL response (typically 4–12 weeks after starting or changing therapy) rather than recalculating the overall risk score. Annual comprehensive metabolic panels can track lipid trends over time.

What if my Reynolds Risk Score gives a different answer than my ASCVD score?

Reynolds and ASCVD use different endpoints and variables, so differences are expected. Reynolds is particularly likely to reclassify intermediate-risk patients upward if they have elevated hsCRP (>2.0 mg/L) or a first-degree relative with premature MI. If your ASCVD score places you in the borderline or intermediate range and your Reynolds score is substantially higher, discuss the discordance with your clinician — it may support adding a statin or obtaining a CAC score.

---

Summary: A Practical Framework for Cardiovascular Risk Assessment

1. Start with the ASCVD Pooled Cohort Equations for adults aged 40–79 without established CVD
2. Place patients in risk category: low (<5%), borderline (5–7.5%), intermediate (7.5–20%), or high (≥20%)
3. For high risk (≥20%): initiate high-intensity statin without delay
4. For intermediate risk (7.5–20%): initiate statin; discuss intensity; optimize all risk factors
5. For borderline risk (5–7.5%): engage in shared decision-making; assess risk enhancers; consider CAC score if uncertain; add statin if enhancers present
6. For low risk (<5%): focus on lifestyle modification; reassess in 4–6 years
7. Always supplement calculators with Reynolds Risk Score (especially in women), family history, inflammatory markers, and CAC scoring when appropriate
8. Treat the whole patient: blood pressure, diabetes, smoking, diet, and exercise are as important as statin therapy

The goal of cardiovascular risk calculators is not to assign a number — it is to facilitate a meaningful conversation between patient and clinician that leads to actions which prevent premature death and disability.

---

Sources

• 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease | Journal of the American College of Cardiology
• 2018 AHA/ACC Guideline on the Management of Blood Cholesterol | Circulation
• 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk | Circulation
• Ridker PM et al. Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women: The Reynolds Risk Score | JAMA 2007
• JUPITER Trial: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein | NEJM 2008
• World Health Organization. Cardiovascular diseases (CVDs) Fact Sheet
• Goff DC Jr et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk | Circulation 2014
• Ference BA et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease | European Heart Journal 2017

---

Disclaimer: This guide is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Cardiovascular risk calculators are tools to support — not replace — individualized clinical judgment. All treatment decisions, including whether to initiate statin therapy, must be made in consultation with a qualified healthcare provider who can evaluate your complete medical history, medications, comorbidities, and personal preferences.